BioTime (BTX)

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy

Cell-Cure-Logo

Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based …

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy Read More »

Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program

BioTime (BTX), via its subsidiary Asterias, has formally purchased the Geron (GERN) embryonic stem cell (ESC) research program and assets. Incidentally, Asterias in nature refers to a genus of sea stars including starfish and you can see it in their logo. Perhaps this was chosen given the amazing regenerative capacity of starfish? You may recall …

Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program Read More »